Purple Biotech Ltd. — Director's Dealing 2026

Apr 17, 2026

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:	3235-0104
Estimated average burden hours per response	0.5
---	---
1. Name and Address of Reporting Person*
GIL EFRON
(Last) (First) (Middle)
4 OPPENHEIMER STREET
SCIENCE PARK
(Street)
REHOVOT 7670104
(City) (State) (Zip/Postal Code)
ISRAEL
(Country)	2. Date of Event Requiring Statement
(Month/Day/Year)
03/18/2026	3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [PPBT]
3a. Foreign Trading Symbol
(Check all applicable)
Director 10% Owner
X Officer Other
(give title below) (specify below)
Chief Executive Officer
(Month/Day/Year)
6. Individual or Joint/Group Filing
(Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I – Non-Derivative Securities Beneficially Owned
---	---
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)
Ordinary Shares	15,750,000(1)
---	---
Table II – Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date
(Month/Day/Year)
	Date Exercisable

---

Stock Option (Right to Buy)	(2)	(2)	Ordinary Shares	1,500,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	3,750,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	13,500,000	(4)	D

Explanation of Responses:

1. Includes 12,375,000 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

2. Represents stock option to purchase 1,500,000 Ordinary Shares (equivalent to 750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.

3. Represents stock option to purchase 3,750,000 Ordinary Shares (equivalent to 1,875 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.0765625 per Ordinary Share and the option expires on July 11, 2027.

4. Represents stock option to purchase 13,500,000 Ordinary Shares (equivalent to 6,750 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 1,125,000 Ordinary Shares are vested and exercisable, with the remaining options to purchase 12,375,000 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030

/s/ Gil Efron
03/31/2026
** Signature of Reporting Person
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.